Σύγκριση μεθόδων

	Ερωτηματολόγιο Επίγνωσης Υπογλυκαιμίας Clarke	AGHDA: Αξιολόγηση Ανεπάρκειας Αυξητικής Ορμόνης σε Ενήλικες
Πεδίο	Ενδοκρινολογία	Ενδοκρινολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	1995	2000
Δημιουργός	William L. Clarke, Don J. Cox, Lois A. Gonder-Frederick	Anthony Hunt, Garry Werther, Peter Wrightson
Τύπος	Patient self-report questionnaire	Patient self-report questionnaire
Θεμελιώδης πηγή	Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995). Reduced awareness of hypoglycemia in adults with IDDM: A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care, 18(6), 517-522.	Hunt, A. E., Werther, G. A., & Wrightson, P. (2000). The utility of AGHDA in identifying GH-deficient adults. Clin Endocrinol (Oxf), 52(3), 341-346.
Εναλλακτικές ονομασίες	HAQ, Clarke HAQ, Hypoglycemia Awareness Scale	AGHDA-25
Συναφείς	3	3
Σύνοψη	The Clarke Hypoglycemia Awareness Questionnaire is an 8-item instrument designed to identify patients with impaired hypoglycemia awareness—a condition in which diabetic patients fail to perceive early warning symptoms of low blood glucose, substantially increasing their risk of severe hypoglycemia. Developed by Clarke and colleagues in 1995, it is the most widely used screening tool for this dangerous complication in type 1 diabetes and in insulin-treated type 2 diabetes populations.	The AGHDA is a 25-item disease-specific quality of life questionnaire designed to assess the burden of adult growth hormone (GH) deficiency. Developed by Hunt, Werther, and colleagues in 2000, it evaluates symptoms and functional impairments directly related to GH deficiency, including fatigue, reduced muscle strength, weight gain, and psychological difficulties. The instrument is widely used in endocrinology practice and clinical trials to quantify the impact of GH replacement therapy.